Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NMK89
- Development stage
- Phase 1
- Lead developer
- Nihon Medi-Physics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
NMK89 is a humanized monoclonal antibody radiolabeled with zirconium-89 (a positron-emitting radionuclide), designed for use as a diagnostic imaging agent in cancer theranostics. It specifically targets MUC5AC, a mucin protein that is overexpressed in pancreatic cancer and several other malignancies including liver, colon, gastric, and lung cancers. By binding to MUC5AC-expressing tumors and being detectable via PET/CT imaging due to the zirconium-89 label, NMK89 enables visualization of tumor burden and metastases. The drug is being developed primarily for improved detection and monitoring of pancreatic cancer but may have broader applications in other MUC5AC-positive cancers. Preclinical studies have demonstrated high tumor specificity with low non-specific uptake in normal tissues[1][2][3][4][5].
- Other names
- NMK89NMK-89NMK 8989Zr-labeled hNd2Anti-muc5ac RDCAnti-muc-5ac RDCAnti-muc 5ac RDC
02
Targets
MUC5AC (Mucin-5AC)
Beyond the preview
Go deeper on NMK89.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NMK89.